Appeal 2007-1040
Application 09/960,708
INTRODUCTION
The claims are directed toward methods of inhibiting (a)
angiogenesis/vascular development in a host (claims 8 and 46) or (b) tumor
growth in a host (claims 15 and 47). The methods of claims 8 and 15
comprise the single step of systemically administering an effective amount
of a Ca2+/calcineurin/NF-ATc inhibitory agent to the host. The methods of
claims 46 and 47 comprise the single step of administering an effective
amount of a cyclosporin to the host. Claims 8, 15, 46, and 47 are
reproduced below:
8. A method of inhibiting angiogenesis/vascular development in a
host having a condition associated with unwanted angiogenesis, said method
comprising:
systemically administering to said host an effective amount of a
Ca2+/calcineurin/NF-ATc inhibitory agent to inhibit angiogenesis/vascular
development in said host having a condition associated with unwanted
angiogenesis.
15. A method of inhibiting tumor growth in a host having a
neoplastic disease condition, said method comprising:
systemically administering to said host having a neoplastic disease
condition an
effective amount of a Ca2+/calcineurin/NF-ATc inhibitory agent to
inhibit tumor growth in said host.
46. A method of inhibiting angiogenesis/vascular development in a
host having a condition associated with unwanted angiogenesis, said method
comprising:
administering to said host an effective amount of a cyclosporin to
inhibit angiogenesis/vascular development in a host having a
condition associated with unwanted angiogenesis.
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 Next
Last modified: September 9, 2013